We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -0.57% | 4.375 | 4.25 | 4.50 | 4.625 | 4.25 | 4.625 | 2,228,810 | 15:04:32 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -0.98 | 5.03M |
From May 2019 to May 2024
TIDMGDR
RNS Number : 0295P
Genedrive PLC
11 November 2016
RNS
For release: 11 November 2016
2016 Annual Report and AGM Notice
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, gives notice that copies of its 2016 Annual Report and Notice of the 2016 Annual General Meeting have been posted to shareholders. The AGM will be held at 11.00am on Wednesday, 30 November 2016 at the the Company's premises at The Innovation Centre, 48 Grafton Street, Manchester M13 9XX.In 2015/16.
Copies of these documents may be found on the Company's website (www.genedriveplc.com)
.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
John Rylands: Finance Director
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) platform and MTB/RIF test have been launched in India and a Genedrive(R) HCV test has been successfully assessed by the Institut Pasteur, Paris.
genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOABRBDBSSBBGLB
(END) Dow Jones Newswires
November 11, 2016 12:47 ET (17:47 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
